“FDA warning letter to Guangzhou Huli (Fantasy Face) for unapproved Googeer GLP-1 Weight Control Oral Solution sold on eBay. Violates FD&C Act; response due in 15 days. Read full details.”
Written By: Pharmacally Medical News Desk
The U.S. Food and Drug Administration (FDA) has issued an advisory letter to Guangzhou Huli Technology Co., Ltd. dba Fantasy Face regarding the online sale of an unapproved drug product marketed for weight control. The agency said it reviewed the company’s eBay store in December 2025 and identified the product, Googeer GLP-1 Weight Control Oral Solution, as being offered for sale to U.S. consumers.
FDA says product qualifies as an unapproved new drug
According to the FDA, the product is considered a drug under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling suggests it is intended to affect body function and support treatment-related outcomes. The agency cited claims such as “Metabolism Support,” “Weight management Blood Sugar Balance,” and “Ideal Body Shaping helps to shape a slim body” as evidence of intended drug use.
The FDA further determined that the product qualifies as a “new drug” under section 201(p) of the FD&C Act because it is not generally recognized as safe and effective for the labelled uses. The agency stated that no FDA-approved application is in effect for this product. As a result, introducing or delivering the product into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.
FDA requests corrective action
The agency noted that the violations described in the letter may not represent all potential compliance issues. The company is responsible for investigating the causes of violations and preventing recurrence, while ensuring compliance with federal law and FDA regulations.
The FDA requested that the firm respond in writing within 15 working days of receiving the letter. The response should outline steps taken to correct violations, actions to prevent recurrence, and supporting documentation. If corrective actions cannot be completed within the specified timeframe, the company must provide justification and a timeline.
The agency warned that failure to adequately address the concerns may lead to regulatory or legal action, including seizure or injunction.
Additional Firms Receive FDA Warning Letters Over GLP-1 Product Sales
The April 7, 2026 postings show the same enforcement action extended to multiple firms marketing unapproved GLP-1 products online. The U.S. Food and Drug Administration issued warning letters to Mile High Compounds LLC, PekCura Labs, Prime Sciences, Lovega LLC dba Pink Pony Peptides, and Gram Peptides on the same date, citing the online marketing of unapproved new drugs promoted for weight loss or metabolic effects. These letters, posted alongside the notice to Guangzhou Huli Technology Co., indicate a broader enforcement sweep targeting internet-based sales of GLP-1–related products that have not undergone FDA review for safety and effectiveness.
Rising FDA Scrutiny of Unapproved GLP-1 Weight Loss Products Sold Online
This warning comes amid increasing regulatory attention from the U.S. Food and Drug Administration on products marketed as GLP-1–based weight loss solutions without approval. The rapid demand for GLP-1 therapies, particularly medicines such as semaglutide marketed under brands including Ozempic and Wegovy, has led to the emergence of online products making similar metabolism, weight management, and blood sugar claims. FDA actions targeting such listings emphasize that products promoted with drug-like claims must undergo regulatory review for safety and effectiveness before being marketed to U.S. consumers.
Reference
Warning Letter, Guangzhou Huli Technology Co., Ltd. dba Fantasy Face, 07 April 2026, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-huli-technology-co-ltd-dba-fantasy-face-722228-03312026
